Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387264976> ?p ?o ?g. }
- W4387264976 endingPage "4823" @default.
- W4387264976 startingPage "4823" @default.
- W4387264976 abstract "Nivolumab, an anti-programmed cell death 1 immuno-oncology therapy, is approved as an adjuvant treatment for patients with completely resected stage III or stage IV melanoma. PRESERV MEL (Prospective and REtrospective Study of nivolumab thERapy in adjuVant MELanoma) is a real-world observational study evaluating the effectiveness and safety of adjuvant nivolumab in patients with completely resected stage III or stage IV melanoma in clinical practice in Belgium and Luxembourg.Patients were enrolled prospectively and retrospectively during a 2-year period (January 2019-January 2021), and will be followed for 5 years. The results reported here are for the second interim analysis (cutoff date 31 December 2021). The index date was the date of first administration of adjuvant nivolumab. Patients received nivolumab for up to 12 months per label. Outcomes included relapse-free survival (RFS), adverse events (AEs)/treatment-related AEs (TRAEs), and health-related quality of life (HRQoL; assessed in prospectively enrolled patients using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30), Functional Assessment of Cancer Therapy-Melanoma (FACT-M), and EQ-5D-3L instruments). HRQoL was evaluated at group level (mean change in scores from baseline based on minimally important differences) and individual patient level (percentage of patients with clinically important scores based on threshold of clinical importance). Outcomes were analyzed descriptively.The study enrolled 152 patients (125 prospective, 27 retrospective) at 15 hospitals in Belgium and Luxembourg. Minimum potential follow-up at time of analysis was 11.4 months. Median age was 60 years (range 29-85), and 53% of patients were male. At 12 and 18 months, the RFS rates were 74.7% (95% confidence interval (CI): 66.9-80.9) and 68.4% (95% CI: 60.0-75.5), respectively. Median RFS was not reached. Grade 3 or 4 TRAEs were reported in 14% of patients. AEs led to treatment discontinuation in 23% of patients. Deaths occurred in 3% of patients and were not related to treatment. Questionnaire completion rates for HRQoL were high at baseline (90-94%) and at 24 months (78-81%). In the group-level analysis for HRQoL, mean changes in scores from baseline remained stable and did not exceed prespecified thresholds for minimally important differences during and after treatment, except for a clinically meaningful improvement in FACT-M surgery subscale scores. In the individual patient-level analysis for EORTC QLQ-C30 subscales, the percentages of patients who reported clinically relevant scores for fatigue and cognitive impairment increased during treatment (at 9 months) compared with baseline. After treatment cessation (at 18 months), the percentage of patients who reported clinically relevant scores for fatigue decreased. However, the percentages of patients who reported clinically relevant scores for emotional, cognitive, and social impairment increased at 18 months compared with during treatment. Most patients with emotional impairment at 9 and 18 months did not experience disease recurrence (91% and 89%, respectively).These results confirm the real-world effectiveness and safety of nivolumab as an adjuvant treatment for patients with completely resected stage III or stage IV melanoma. Cancer-specific, disease-specific, and generic HRQoL were maintained during and after treatment. The percentage of patients reporting emotional and cognitive impairment increased after treatment cessation, emphasizing the need for further investigation and tailored supportive care in these patients." @default.
- W4387264976 created "2023-10-03" @default.
- W4387264976 creator A5024431309 @default.
- W4387264976 creator A5027460834 @default.
- W4387264976 creator A5035681529 @default.
- W4387264976 creator A5042997291 @default.
- W4387264976 creator A5053176640 @default.
- W4387264976 creator A5061310686 @default.
- W4387264976 creator A5071384199 @default.
- W4387264976 creator A5082449165 @default.
- W4387264976 creator A5087842420 @default.
- W4387264976 date "2023-09-30" @default.
- W4387264976 modified "2023-10-17" @default.
- W4387264976 title "Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL" @default.
- W4387264976 cites W1947168884 @default.
- W4387264976 cites W1967231311 @default.
- W4387264976 cites W1994222210 @default.
- W4387264976 cites W1996298284 @default.
- W4387264976 cites W2098428600 @default.
- W4387264976 cites W2149564130 @default.
- W4387264976 cites W2150982823 @default.
- W4387264976 cites W2153836018 @default.
- W4387264976 cites W2167571044 @default.
- W4387264976 cites W2752227448 @default.
- W4387264976 cites W2757095060 @default.
- W4387264976 cites W2897468620 @default.
- W4387264976 cites W2898518424 @default.
- W4387264976 cites W2906639914 @default.
- W4387264976 cites W2922462565 @default.
- W4387264976 cites W2941779578 @default.
- W4387264976 cites W2980779881 @default.
- W4387264976 cites W2990928375 @default.
- W4387264976 cites W3012372578 @default.
- W4387264976 cites W3026473018 @default.
- W4387264976 cites W3045053679 @default.
- W4387264976 cites W3084990964 @default.
- W4387264976 cites W3087697977 @default.
- W4387264976 cites W3155422251 @default.
- W4387264976 cites W4210844938 @default.
- W4387264976 cites W4229079437 @default.
- W4387264976 cites W4280528686 @default.
- W4387264976 cites W4291012346 @default.
- W4387264976 cites W4292186446 @default.
- W4387264976 cites W4297094017 @default.
- W4387264976 cites W4321189182 @default.
- W4387264976 doi "https://doi.org/10.3390/cancers15194823" @default.
- W4387264976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37835517" @default.
- W4387264976 hasPublicationYear "2023" @default.
- W4387264976 type Work @default.
- W4387264976 citedByCount "0" @default.
- W4387264976 crossrefType "journal-article" @default.
- W4387264976 hasAuthorship W4387264976A5024431309 @default.
- W4387264976 hasAuthorship W4387264976A5027460834 @default.
- W4387264976 hasAuthorship W4387264976A5035681529 @default.
- W4387264976 hasAuthorship W4387264976A5042997291 @default.
- W4387264976 hasAuthorship W4387264976A5053176640 @default.
- W4387264976 hasAuthorship W4387264976A5061310686 @default.
- W4387264976 hasAuthorship W4387264976A5071384199 @default.
- W4387264976 hasAuthorship W4387264976A5082449165 @default.
- W4387264976 hasAuthorship W4387264976A5087842420 @default.
- W4387264976 hasBestOaLocation W43872649761 @default.
- W4387264976 hasConcept C121608353 @default.
- W4387264976 hasConcept C126322002 @default.
- W4387264976 hasConcept C141071460 @default.
- W4387264976 hasConcept C143998085 @default.
- W4387264976 hasConcept C146357865 @default.
- W4387264976 hasConcept C151730666 @default.
- W4387264976 hasConcept C159110408 @default.
- W4387264976 hasConcept C167135981 @default.
- W4387264976 hasConcept C188816634 @default.
- W4387264976 hasConcept C197934379 @default.
- W4387264976 hasConcept C23131810 @default.
- W4387264976 hasConcept C2777658100 @default.
- W4387264976 hasConcept C2777701055 @default.
- W4387264976 hasConcept C2777982462 @default.
- W4387264976 hasConcept C2779951463 @default.
- W4387264976 hasConcept C2780030458 @default.
- W4387264976 hasConcept C502942594 @default.
- W4387264976 hasConcept C535046627 @default.
- W4387264976 hasConcept C61943457 @default.
- W4387264976 hasConcept C71924100 @default.
- W4387264976 hasConcept C86803240 @default.
- W4387264976 hasConceptScore W4387264976C121608353 @default.
- W4387264976 hasConceptScore W4387264976C126322002 @default.
- W4387264976 hasConceptScore W4387264976C141071460 @default.
- W4387264976 hasConceptScore W4387264976C143998085 @default.
- W4387264976 hasConceptScore W4387264976C146357865 @default.
- W4387264976 hasConceptScore W4387264976C151730666 @default.
- W4387264976 hasConceptScore W4387264976C159110408 @default.
- W4387264976 hasConceptScore W4387264976C167135981 @default.
- W4387264976 hasConceptScore W4387264976C188816634 @default.
- W4387264976 hasConceptScore W4387264976C197934379 @default.
- W4387264976 hasConceptScore W4387264976C23131810 @default.
- W4387264976 hasConceptScore W4387264976C2777658100 @default.
- W4387264976 hasConceptScore W4387264976C2777701055 @default.
- W4387264976 hasConceptScore W4387264976C2777982462 @default.
- W4387264976 hasConceptScore W4387264976C2779951463 @default.
- W4387264976 hasConceptScore W4387264976C2780030458 @default.